Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

This is a phase 2, single-arm, open label clinical trial determining efficacy of Cyclophosphamide and Pembrolizumab in subjects with melanoma.

NCT Number	NCT06771544
Lead Sponsor	University of California, Irvine
Conditions	Melanoma, Melanoma Stage III, Melanoma (Skin), Melanoma Stage IV
Enrollment	14 participants
Start Date	2024-12-23
Primary Completion	2027-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-03-10